Kuo MT, et al. - In this retrospective-prospective study, researchers compared hepatitis B virus (HBV) relapse rates in chronic hepatitis B (CHB) patients without cirrhosis who discontinued entecavir (ETV) or tenofovir disoproxil fumarate (TDF). Study participants included 342 CHB patients (108 hepatitis B e antigen (HBeAg)-positive and 234 HBeAg-negative) who received ETV and 165 (46 HBeAg-positive, 119 HBeAg-negative) who received TDF. As compared to patients who discontinued ETV, those who discontinued TDF had significantly higher rates and earlier times of virological and clinical relapse. They observed that HBV relapse occurs earlier and is more severe after TDF cessation than after ETV cessation.